Spanish drugmaker PharmaMar (MC: PHM) and Taiwanese company TTY Biopharm have announced an exclusive licensing agreement for the import, use, marketing, sale and distribution of the marine-derived anticancer drug Yondelis (trabectedin) in Taiwan, Hong Kong and Macao.
Under the terms of the agreement, PharmaMar will receive a non-disclosed upfront sum and will also be eligible for an additional regulatory milestone payment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze